Bloomberg — 2026-04-19#

Lead Story#

Tensions in the Middle East reached a new peak after the US Navy forcibly seized an Iranian-flagged cargo ship in the Gulf of Oman, blowing a hole in its engine room. The dramatic escalation prompted Iranian authorities to shut down the Strait of Hormuz to commercial shipping after a brief reopening, sending oil and gasoline prices surging and reviving broad global market volatility.

Markets & Economics#

• Big Tech’s $4 Trillion Boomerang Powers S&P 500 to New Heights: Despite geopolitical anxieties stemming from the Iran war, a massive resurgence in mega-cap technology stocks is driving the S&P 500 to fresh records. Options traders have pivoted away from macro fear to pure “fear of missing out” ahead of major corporate earnings.
• Next Catalyst for Treasury Bonds Is Named Kevin Warsh: Bond markets are shifting their focus to Capitol Hill, where traders are bracing for the April 21 confirmation hearing of Kevin Warsh, President Donald Trump’s nominee for Federal Reserve chair.
• ECB Better Off to Wait Than Rush Into Rate Action, Demarco Says: Governing Council member Alexander Demarco cautioned that the European Central Bank should delay raising borrowing costs, arguing that high uncertainty surrounding the Middle East conflict requires a wait-and-see approach.
• Emerging-Market Bond Sales Are Soaring Again as Investors Dive Back Into Risk: Following a sluggish March, sovereign and corporate issuers from Brazil to Turkey are successfully tapping debt markets again as investors regain their appetite for risk.

Business & Industries#

• QXO to Buy TopBuild in $17 Billion Building Products Deal: Brad Jacobs’s QXO Inc. is acquiring insulation giant TopBuild Corp., a blockbuster transaction that will transform QXO into North America’s second-largest publicly traded building products distributor.
• Bezos’ Blue Origin Launches New Glenn Rocket With AST Satellite: Blue Origin successfully reused and recovered a booster for its flagship New Glenn rocket, confirming a critical technical milestone that will allow Jeff Bezos’s company to drastically increase launch cadences and rival SpaceX.
• Vitol Made About $2 Billion in First Quarter Despite War Losses: The world’s top energy trader reported a massive first-quarter profit to its lenders, seeking to soothe concerns over targeted business losses directly resulting from the Iran conflict.
• China’s Orient Securities Deal to Create $86 Billion Brokerage: Shanghai is merging two government-backed brokerages to form a powerhouse with $86 billion in assets, accelerating Beijing’s broader push to consolidate the securities industry and forge world-class investment banks.

Policy & World#

• Trump Says Witkoff is Heading to Pakistan for Iran Talks: US President Donald Trump is dispatching special envoy Steve Witkoff to Islamabad for renewed peace negotiations with Iran. The talks arrive as the conflict cripples energy supplies, plunging host nation Pakistan into rolling blackouts.
• Bulgarian Russia-Sympathizer Radev Secures Decisive Election Win: Former President Rumen Radev, a staunch critic of Russian sanctions and military aid to Ukraine, claimed an overwhelming victory in Bulgaria’s eighth general election since 2021, potentially ending years of gridlock.
• Starmer Nears Showdown With Sacked Official Over Mandelson Saga: UK Prime Minister Keir Starmer’s cabinet is rallying to his defense amid mounting calls for his resignation over the controversial appointment of Peter Mandelson as US ambassador.
• China Deploys Warship for Combat Drills in Western Pacific: The Chinese People’s Liberation Army is expanding its maritime reach, conducting rare military exercises beyond a key chain of archipelagos in a direct challenge to US naval dominance.

Opinion & Analysis#

• SoftBank Is Going All In on OpenAI, But at What Cost?: Bloomberg Opinion explores Masayoshi Son’s aggressive gamble to acquire OpenAI shares, warning that the transaction risks exposing SoftBank to a dangerous liquidity crunch.
• China’s Pharma Dominance Is Just Beginning: The old pharmaceutical order driven primarily by the West has vanished, replaced by a US-China bipolar landscape that carries massive implications for global policymakers and patients.